Title: Antibiotics of LegoChem selected for
"Pharm Navi" project Publication: Health Korea News / Sun-Ho Lee Date: 17 Oct 2014 URL: link to website (contents in Korean)
Summary
·
Ministry
of Food and Drug Safety in Korea selected LegoChem Biosciences' Oxazolidinone
antibiotics project (LCB01-0371) as the second "Pharm Navi" proejct
for rapid commercialization of new medicines developed in domestic and
supporting global expansion. ·
LegoChem’s
LCB01-0371 project for oral administration is now completing Phase I, and the
intravenous administration is soon entering the clinical stage. About LegoChem
Biosciences
LegoChem Biosciences,
Inc. (LCB) is a research-based biotechnology company dedicated to discovering,
developing, and commercializing innovative medicines by leveraging our
chemistry expertise to make conventional biologics targeted and more potent for
the benefit of patients with diseases of high unmet medical needs. We are
advancing sustainable pipelines in therapeutic areas in antibiotics,
anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug
conjugate (PDC). | 
